Evaluation of the potential of Ergostatrien‐3β‐ol for treating Sjögren's syndrome
Our findings suggest that EK100 may offer a promising therapeutic avenue for the treatment of SS by modulating the interaction between Th17 cells and DCs.
Authors
- Po‐Chang Wu (ORCID: https://orcid.org/0000-0001-8109-6996)
- Ya‐Hsuan Chao (ORCID: https://orcid.org/0000-0001-8283-6589)
- Yueh‐Hsiung Kuo (ORCID: https://orcid.org/0000-0001-5935-6755)
- Hen‐Hong Chang (ORCID: https://orcid.org/0000-0002-7840-1504)
- Xiang Zhang (ORCID: https://orcid.org/0000-0002-4239-0145)
- Tzu‐Ting Chen
- Chi-Wei Lin (ORCID: https://orcid.org/0009-0006-0133-6173)
Institutions
- Asia University (TW)
- Kaohsiung Medical University (TW)
- National Chung Hsing University (TW)
- China Medical University (TW)
- National Tsing Hua University (TW)
- Karolinska Institutet (SE)
- China Medical University Hospital (TW)
Publication Details
- Journal
- International Journal of Rheumatic Diseases
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1111/1756-185x.15341
- Citations
- 1
- Primary Topic
- Salivary Gland Disorders and Functions
- Type
- article
- Field-Weighted Citation Impact
- 0.33